immatics has a solid financial basis, with leading international life science investors supporting its business.
Through its series A financing round in 2004/2005, immatics raised more than € 14 million from top tier venture capital firms.
In February 2007, in addition to the existing consortium, Dietmar Hopp as the new lead investor together with new co-investors, committed additional € 40 million to support the success story of immatics.
A series C financing round of €54 million was raised in September 2010 with approximately half of the investment coming from new investors MIG AG and AT Impf GmbH.
AT Impf GmbH
Dievini Hopp BioTech Holding GmbH & Co.KG
National Technology Enterprises Company